Endogena Completes Series A with Total Funding of $29 million to Progress Treatments for Degenerative Diseases of the Eye

We are thrilled today to announce that its largest shareholder and lead operating partner Rejuveron Life Sciences AG, has committed a further $20 million funding to progress treatments targeting degenerative diseases of the eye. With an additional $1 million from existing investors, Endogena has now completed its $29 million Series A financing round.

Matthias Steger, CEO of Endogena, said: “We are on the brink of a critical milestone in our development as we progress our first program into the clinic. This would not be possible without the substantial support of Rejuveron and DEFTA. Our small molecule drug discovery expertise, AI-driven platform combined with our stateof-the-art stem cell know-how will enable us to advance breakthrough therapies in several indications.”

Christian Angermayer, Chairman of Rejuveron Life Sciences AG, said: “Endogena Therapeutics’ approach for endogenous regenerative medicine is a novel treatment paradigm for common degenerative diseases that are becoming more prevalent due to demographic changes with aging populations. Rejuveron is focused on advancing treatments that focus on the biology of ageing and Endogena has transformative potential for age-related degenerative diseases. Regenerative therapies will have a more prominent role in expanding the healthspan of our aging population, which is facing the increasing burden of social, economic and healthcare challenges of age-related demographic shifts.”

Elona Baum, Managing Director of DEFTA Partners, said: “DEFTA Partners is a strong supporter of funding innovation in age related diseases and is pleased to be working with Rejuveron to support Endogena’s innovative pipeline.”

Find out more here.